MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Organon & Co

Chiusa

SettoreSettore sanitario

9.93 -1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.73

Massimo

10.06

Metriche Chiave

By Trading Economics

Entrata

-22M

87M

Vendite

-79M

1.5B

P/E

Media del settore

3.375

39.564

Rendimento da dividendi

0.83

Margine di Profitto

5.75

Dipendenti

10,000

EBITDA

-13M

325M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+33.33% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.83%

2.40%

Utili prossimi

5 ago 2025

Prossima data del Dividendo

11 set 2025

Prossima data del' Ex Dividendo

15 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.6B

2.5B

Apertura precedente

10.93

Chiusura precedente

9.93

Notizie sul Sentiment di mercato

By Acuity

50%

50%

174 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Organon & Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 lug 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 lug 2025, 17:28 UTC

I principali Market Mover

SharpLink Gaming Gains on Ethereum Purchase

11 lug 2025, 16:57 UTC

Utili

BASF Cuts Outlook on Global Economy Uncertainty

11 lug 2025, 21:45 UTC

Discorsi di Mercato

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 lug 2025, 19:46 UTC

Acquisizioni, Fusioni, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 lug 2025, 19:45 UTC

Discorsi di Mercato

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 lug 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 lug 2025, 18:18 UTC

Discorsi di Mercato

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 lug 2025, 17:35 UTC

Discorsi di Mercato

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 lug 2025, 17:26 UTC

Discorsi di Mercato

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 lug 2025, 16:53 UTC

Discorsi di Mercato

Crude Futures Add to Early Gains -- Market Talk

11 lug 2025, 16:42 UTC

Utili

BASF Cuts Outlook on Global Economic Uncertainty

11 lug 2025, 16:08 UTC

Discorsi di Mercato

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 lug 2025, 16:05 UTC

Utili

BASF Will Publish Half-Year Results on July 30

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 lug 2025, 16:03 UTC

Utili

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 lug 2025, 16:02 UTC

Utili

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 lug 2025, 16:01 UTC

Utili

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 lug 2025, 16:00 UTC

Utili

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 lug 2025, 15:59 UTC

Utili

BASF Cuts 2025 Earnings View

11 lug 2025, 15:58 UTC

Utili

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 lug 2025, 15:57 UTC

Utili

BASF 2Q EBIT Before Special Items EUR810M

11 lug 2025, 15:54 UTC

Utili

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 lug 2025, 15:54 UTC

Utili

BASF 2Q Sales Fell 2.1% on Year

11 lug 2025, 15:53 UTC

Utili

BASF 2Q Sales EUR15.77B

11 lug 2025, 15:52 UTC

Utili

BASF: This Was in Line With Consensus Estimates

11 lug 2025, 15:52 UTC

Utili

BASF 2Q Ebitda Before Special Items EUR1.77B

11 lug 2025, 15:49 UTC

Utili

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 lug 2025, 15:41 UTC

Discorsi di Mercato

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Confronto tra pari

Modifica del prezzo

Organon & Co Previsione

Obiettivo di Prezzo

By TipRanks

33.33% in crescita

Previsioni per 12 mesi

Media 13.36 USD  33.33%

Alto 18 USD

Basso 9.5 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Organon & Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

2

Acquista

4

Mantieni

2

Vendi

Punteggio Tecnico

By Trading Central

8.53 / 9.18Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

174 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.